What Researchers Did
Researchers compared the duration of treatment implementation and reported symptoms for patients with Sudden Sensorineural Hearing Loss before and during the COVID-19 pandemic.
What They Found
The 34 surveyed patients (average age 46.3) experienced significantly delayed pharmacotherapy implementation during the pandemic (12.08 days) compared to before (5.41 days). Hyperbaric oxygen therapy was also delayed (17.5 days during pandemic vs. 8.29 days before), and there were differences in reported symptoms.
What This Means for Canadian Patients
Canadian patients with sudden sensorineural hearing loss could face delayed access to critical treatments like pharmacotherapy and hyperbaric oxygen therapy during public health emergencies. Timely intervention is crucial for SSNHL, suggesting that healthcare systems need robust strategies to maintain essential services during crises.
Canadian Relevance
This study was conducted in Poland and has no direct Canadian connection.
Study Limitations
A limitation of this study is its small sample size of 34 patients from a single institution, which may limit generalizability.